• ¿Documento equivocado? Cámbialo gratis
  • Escrito por estudiantes que aprobaron
  • Inmediatamente disponible después del pago
  • Leer en línea o como PDF
Vender
¿Dónde estudias?
Tu idioma
Document preview thumbnail
Vista previa 2 fuera de 10 páginas
Examen

Pharmacology Master Review & Board Exam USMLE Step 1, Step 2 CK, NCLEX-RN & PharmD Curriculum Standard • Vol. 1

Document preview thumbnail
Vista previa 2 fuera de 10 páginas

*Pharmacology Master Review & Board Exam*, Volume 1 provides focused study support for students preparing for major healthcare examinations and pharmacology coursework. It reinforces essential concepts including pharmacokinetics, pharmacodynamics, drug classifications, mechanisms of action, adverse effects, contraindications, drug interactions, and therapeutic applications. Designed to support preparation for USMLE Step 1, USMLE Step 2 CK, NCLEX-RN, and PharmD curricula, this review resource helps learners connect pharmacological principles with clinical decision-making. Its organized coverage makes it useful for comprehensive revision, strengthening medication knowledge, identifying weak areas, and building confidence before high-stakes assessments.

Vista previa del contenido

Pharmacology Master Review & Board Exam
USMLE Step 1, Step 2 CK, NCLEX-RN & PharmD Curriculum Standard • Vol. 1




High-Yield Review Note: This volume covers key foundational principles in Pharmacokinetics, Pharmacodynamics,
Autonomic Nervous System, Cardiovascular, Renal, Central Nervous System, Endocrine, Antimicrobial, and Oncology
Therapeutics.



MODULE 1: PRINCIPLES OF PHARMACOKINETICS & PHARMACODYNAMICS


1. An experimental drug demonstrates a clearance of 10 L/hr and a volume of distribution of 100 L. What is the
calculated elimination half-life (t1/2)?

• A. 3.5 hours ✓ B. 6.93 hours
• C. 10.0 hours • D. 14.4 hours

Rationale: Half-life equation: t1/2 = (0.693 × Vd) / CL = (0.693 × 100) / 10 = 6.93 hours.




2. Which parameter determines the time required for a continuous IV drug infusion to reach steady-state
concentration in plasma?

• A. Infusion rate (k0) ✓ B. Elimination half-life (t1/2)
• C. Bioavailability (F) • D. Loading dose

Rationale: The time to reach steady state depends strictly on the drug's elimination half-life (~4 to 5 half-lives), completely
independent of dose size or infusion rate.




3. A non-competitive antagonist affects an agonist's dose-response curve by causing which of the following
changes?

• A. Parallel shift to the right ✓ B. Decrease in maximal response (Emax)
• C. Increase in potency (lower EC50) • D. Parallel shift to the left

Rationale: Non-competitive antagonists bind allosterically or irreversibly, decreasing Emax without changing the agonist's
affinity (EC50).




Pharmacology Master Examination • Volume 1 Page 1 of 10

, MODULE 2: AUTONOMIC NERVOUS SYSTEM PHARMACOLOGY


4. A patient presenting with cholinergic crisis after exposure to organophosphate nerve agents should
immediately receive which combination of drugs?

• A. Physostigmine + Edrophonium ✓ B. Atropine + Pralidoxime
• C. Neostigmine + Glycopyrrolate • D. Pilocarpine + Methacholine

Rationale: Atropine blocks excess muscarinic stimulation, while Pralidoxime reactivates acetylcholinesterase at nicotinic
sites to reverse muscle paralysis.




5. Pretreatment with which receptor antagonist blocks epinephrine-induced hyperglycemia and vasodilation?

• A. Alpha-1 antagonist ✓ B. Beta-2 antagonist
• C. Muscarinic M3 antagonist • D. Nicotinic Nn antagonist

Rationale: Epinephrine stimulates glycogenolysis in liver/skeletal muscle and vasodilation in skeletal muscle vascular
beds via Beta-2 receptors.




6. Which selective alpha-2 adrenergic agonist is utilized in ICU settings for sedation without inducing
significant respiratory depression?

• A. Clonidine ✓ B. Dexmedetomidine
• C. Phenylephrine • D. Midodrine

Rationale: Dexmedetomidine is a highly selective central alpha-2 agonist providing sedation and analgesia with minimal
respiratory depression.




7. A 60-year-old male with benign prostatic hyperplasia (BPH) and hypertension is prescribed Tamsulosin.
What explains its low risk of orthostatic hypotension?

✓ A. Selective Alpha-1A receptor blockade • B. Non-selective Alpha-1 and Beta-1 blockade

• C. Direct smooth muscle relaxation via nitric oxide • D. Central inhibition of sympathetic outflow

Rationale: Tamsulosin selectively targets Alpha-1A receptors located primarily in the prostate bladder neck, sparing Alpha-
1B receptors in vascular smooth muscle.




Pharmacology Master Examination • Volume 1 Page 2 of 10

Información del documento

Subido en
4 de octubre de 2026
Número de páginas
10
Escrito en
2026/2027
Tipo
Examen
Contiene
Preguntas y respuestas
$19.49

¿Documento equivocado? Cámbialo gratis Dentro de los 14 días posteriores a la compra y antes de descargarlo, puedes elegir otro documento. Puedes gastar el importe de nuevo.
Escrito por estudiantes que aprobaron
Inmediatamente disponible después del pago
Leer en línea o como PDF

Vendido
4
Seguidores
0
Artículos
222
Última venta
5 horas hace



Por qué los estudiantes eligen Stuvia

Creado por compañeros estudiantes, verificado por reseñas

Calidad en la que puedes confiar: escrito por estudiantes que aprobaron y evaluado por otros que han usado estos resúmenes.

¿No estás satisfecho? Elige otro documento

¡No te preocupes! Puedes elegir directamente otro documento que se ajuste mejor a lo que buscas.

Paga como quieras, empieza a estudiar al instante

Sin suscripción, sin compromisos. Paga como estés acostumbrado con tarjeta de crédito y descarga tu documento PDF inmediatamente.

Student with book image

“Comprado, descargado y aprobado. Así de fácil puede ser.”

Alisha Student

Preguntas frecuentes